Sarepta Therapeutics (NASDAQ:SRPT) Given New $182.00 Price Target at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT) had its price target reduced by equities research analysts at Piper Sandler from $200.00 to $182.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Piper Sandler’s price objective suggests a potential upside of 31.94% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. UBS Group upped their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Barclays decreased their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, HC Wainwright assumed coverage on shares of Sarepta Therapeutics in a research report on Monday. They set a “sell” rating and a $80.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $175.77.

Sarepta Therapeutics Trading Up 5.7 %

NASDAQ SRPT opened at $137.94 on Wednesday. Sarepta Therapeutics has a 52 week low of $78.67 and a 52 week high of $173.25. The company has a 50 day moving average price of $122.16 and a 200 day moving average price of $131.43. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market cap of $13.18 billion, a PE ratio of 110.35 and a beta of 0.81.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the business. Tidal Investments LLC raised its stake in shares of Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after buying an additional 2,688 shares during the period. World Investment Advisors LLC purchased a new position in Sarepta Therapeutics during the third quarter valued at $2,418,000. Sunbelt Securities Inc. grew its position in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares during the period. Geode Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock worth $211,910,000 after purchasing an additional 44,306 shares in the last quarter. Finally, M&T Bank Corp raised its position in shares of Sarepta Therapeutics by 8.5% during the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company’s stock worth $558,000 after purchasing an additional 349 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.